Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling

Author:

Doan Tan N.123,Cao Pengxing4,Emeto Theophilus I.25,McCaw James M.4678,McBryde Emma S.12

Affiliation:

1. Department of Medicine at The Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia

2. Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia

3. Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia

4. School of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, Australia

5. College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Queensland, Australia

6. Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia

7. Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, Victoria, Australia

8. Peter Doherty Institute for Infection and Immunity, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia

Abstract

Short-course regimens for multidrug-resistant tuberculosis (MDR-TB) are urgently needed. Limited data suggest that the new drug bedaquiline (BDQ) may have the potential to shorten MDR-TB treatment to less than 6 months when used in conjunction with standard anti-TB drugs.

Funder

University of Melbourne

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference45 articles.

1. World Health Organization. 2018. Global tuberculosis report 2017. World Health Organization, Geneva, Switzerland. www.who.int/tb/publications/global_report/en/.

2. Promoting adherence to treatment for tuberculosis: the importance of direct observation;Frieden TR;World Hosp Health Serv,2007

3. Directly observed therapy for treating tuberculosis;Karumbi J;Cochrane Database Syst Rev,2015

4. Efficient Intermittent Rifapentine-Moxifloxacin-Containing Short-Course Regimen for Treatment of Tuberculosis in Mice

5. Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3